Literature DB >> 1892147

Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome.

D W Denning1, R W Armstrong, B H Lewis, D A Stevens.   

Abstract

Increased intracranial pressure has been a noteworthy problem in some of our patients with cryptococcal meningitis and acquired immunodeficiency syndrome (AIDS), and this appears to be a feature observed in patients with cryptococcal meningitis reported in the literature. Whereas most attention of clinicians is presently focused on optimizing the antifungal regimen, so as to improve on high failure rates in cryptococcal meningitis in AIDS, little attention has been paid to the problem of intracranial hypertension. We argue that visual loss and some of the cases of death early after the onset of chemotherapy may be related to high cerebrospinal fluid (CSF) pressure, regardless of antifungal therapy. The possible pathophysiologic mechanisms are discussed, and we postulate that the mechanism is reduced CSF outflow possibly due to increased outflow resistance, not necessarily accompanied by prominent cerebral edema. Optimal therapy of this complication is not yet established, but some measures that may be helpful are ventricular shunting, frequent high-volume lumbar punctures, and possibly glucocorticoids.

Entities:  

Mesh:

Year:  1991        PMID: 1892147     DOI: 10.1016/0002-9343(91)90126-i

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  46 in total

1.  Cryptococcal Meningitis in HIV-Infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

3.  Raised ICP in a child with cryptococcal meningitis: CT evidence of a distal CSF block.

Authors:  J F Schoeman; E M Honey; D B Loock
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

4.  Relevance of intracranial hypertension control in the management of Cryptococcus neoformans meningitis related to AIDS.

Authors:  L de Vedia; A Arechavala; M I Calderón; E Maiolo; A Rodríguez; N Lista; E Di Virgilio; J C Cisneros; R Prieto
Journal:  Infection       Date:  2013-12       Impact factor: 3.553

5.  Deafness and blindness in a HIV-positive patient with cryptococcal meningitis.

Authors:  J L Prada; J Torre-Cisneros; J M Kindelan; R Jurado; J L Villanueva; M Navarro; M J Linares
Journal:  Postgrad Med J       Date:  1996-09       Impact factor: 2.401

6.  Cryptococcal encephalitis with fulminant intracranial hypertension mimicking anti-NMDA receptor encephalitis.

Authors:  Mirko Piola; Nerina Mascoli; Salvatore Barca; Marco Arnaboldi; Vincenzo Belcastro
Journal:  Neurol Sci       Date:  2014-10-21       Impact factor: 3.307

7.  Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms.

Authors:  L Ostrosky-Zeichner; J L Soto-Hernandez; V Angeles-Morales; F Teixeira; C Nava-Ruiz; C Rios; F Solis; J Sotelo
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

8.  Management of Increased Intracranial Pressure in Cryptococcal Meningitis.

Authors:  Kimberly J. Gambarin; Richard J. Hamill
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

Review 9.  Cryptococcal Disease in HIV-Infected Children.

Authors:  Carol Kao; David L Goldman
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

10.  Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis.

Authors:  Richard Ssekitoleko; Moses R Kamya; Arthur L Reingold
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.